Anle138b ameliorates pathological phenotypes in mouse and cellular models of Huntington’s disease
Miguel da Silva Padilha, Seda Koyuncu, Evangeline Chabanis, Sergey Ryazanov, Andrei Leonov, David Vilchez, Rüdiger Klein, Armin Giese, Christian Griesinger, Irina Dudanova · 2026
Read Anle138b ameliorates pathological phenotypes in mouse and cellular models of Huntington’s disease by Miguel da Silva Padilha, Seda Koyuncu, Evangeline Chabanis, Sergey Ryazanov, Andrei Leonov, David Vilchez, Rüdiger Klein, Armin Giese, Christian Griesinger, Irina Dudanova (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13365221.txt.
Description
Miguel Padilha and co-workers test in 2026 a drug named anle138b in cell and mouse models of Huntington disease, a gene ill that wastes the brain and has no cure. The drug reshapes harm clumps of the ill protein. Treated brain cells made few clumps and took less harm.
Mice on the drug by mouth showed late clump build, less brain waste, calm swell, and betters steps and life span. Brain marks and nerve links lost in the ill came part way back. Human stem cells from patients also clumped less. No harm shows in well mice, a hope for trials.
Catalog record
| CREATOR | Miguel da Silva Padilha, Seda Koyuncu, Evangeline Chabanis, Sergey Ryazanov, Andrei Leonov, David Vilchez, Rüdiger Klein, Armin Giese, Christian Griesinger, Irina Dudanova |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 87885 |
| LICENSE | https://creativecommons.org/publicdomain/zero/1.0 |
| RIGHTS | CC0 |
| SOURCE | Europe PMC |